IRVINE, Calif., March 1, 2006 (PRIMEZONE) -- "Clearly, institutional investors are surveying the biotech landscape looking for opportunities," stated SmallCap Sentinel analyst D.R. Clark. "For example, Callisto Pharmaceuticals (AMEX:KAL) recently announced a $5.14 million private placement, which the company says they will use to continue to fund its strategic initiatives, including substantial clinical development activities in 2006 and additional pre-clinical development activities."
"The Company's latest initiatives include plans to launch an additional clinical trial of its drug candidate Atiprimod, based on recently announced encouraging clinical results that showed a clear response in a patient with advanced carcinoid cancer, plus additional encouraging clinical data on other carcinoid patients," said Clark. "The new data not only transforms the development path for Atiprimod, but has the potential to give Callisto its first approved drug considerably earlier than the Company previously expected."
"Callisto has attracted industry recognition and further financial support for its expanding clinical programs," continued Clark. "This provides a strong indication as to the potential of its products and the likelihood of commercial success. This is not the stuff of an unproven startup."
Callisto Pharmaceuticals is a biopharmaceutical company committed to developing innovative anti-cancer drugs to treat blood cancers and related diseases, including acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), relapsed or refractory multiple myeloma, and osteolytic disease. Callisto also has drugs in pre-clinical development for gastrointestinal inflammation, as well as for protection against the potential bio-warfare agents, staphylococcus and streptococcus.
A detailed informational report regarding Callisto Pharmaceuticals is available free to the public at the following link: http://www.trilogy-capital.com/kal_summary.aspx
The informational report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs" is available at www.SmallCapSentinel.com and will address a variety of biotech and pharmaceutical related issues for companies including Merck (NYSE:MRK), Pfizer (NYSE:PFE), Glaxosmithkline PLC (NYSE:GSK), and Callisto Pharmaceuticals (AMEX:KAL).
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy, nor offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid $1,500 by Callisto for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.